Although CMS had finalized its decision to place the new molecular pathology codes on the Clinical Lab Fee Schedule, a number of questions still remain regarding how payor reimbursement will be affected by the removal of stacking codes. Learn about the latest coding rule decisions, what you should be paying attention to, and the submissions and appeals actions you need to take to protect your lab’s reimbursement in 2013. Join industry experts Bonnie Ancone and Kyle Fetter, of XIFIN’sMolecular Diagnostic Services group, as they discuss in a webinar how these coding changes will affect reimbursement, what you should do to avoid denials and underpayments, and how to optimize your appeals process for maximum reimbursement protection. |  |
Appeals are likely to become an important tool for laboratories in 2013, especially for those forced to submit under Not Otherwise Classified (NOC) codes. Our experts will discuss how to determine when an appeal makes sense, and how to set up automated workflows that take advantage of appeals opportunities without increasing overhead or negatively impacting billing staff workloads.
